ASCO® CENTRA

Center for Research & Analytics

Data Table	Field Name	Field Label	Description
Demographics	LibraryID	Library Participant ID	Unique identifier for each participant across TAPUR Study data sets in the ASCO data library
Demographics	T01AGE	Participant Age	Participant's calculated age if less than 90 years
Demographics	T01AGE90	Participant Age > 90	Selected if participant's age is greater than 90 years
Demographics	T01CNSTDT	Consent Time Interval	Time interval between informed consent/assent was signed by participant and/or legal guardian and baseline visit in days. Note that all time intervals are calculated from the baseline visit so negative intervals indicate days before the baseline visit.
Demographics	T01ETH_STD	Ethnicity	Participant's self-reported ethnicity
Demographics	T01PREVCOHORT_STD	Previous Enrollment	Indicates if participant has been previously enrolled in the TAPUR Study (received at least one dose of study drug)
Demographics	T01PREVDRUG_STD	Previous Enrollment Drug	If participant has been previously enrolled, indicates which study drug treatment they received
Demographics	T01RACE_STD	Race	Participant's self-reported race
Demographics	T01SEX_STD	Biological Sex	Participant's self-reported biological sex
Cancer Medical Treatment History	LibraryID	Library Participant ID	Unique identifier for each participant across TAPUR Study data sets in the ASCO data library
Cancer Medical Treatment History	T03DIADT	Cancer Diagnosis Time Interval	Time interval between participant's initial cancer diagnosis and baseline visit in days. Note that all time intervals are calculated from the baseline visit so negative intervals indicate days before the baseline visit.
Cancer Medical Treatment History	T03STAGE_STD	Cancer Stage at Diagnosis	The cancer stage at initial diagnosis (e.g., IV)
Cancer Medical Treatment History	T03TUMOR_STD	Tumor Type	The tumor type (e.g., Solid tumor)
Cancer Medical Treatment History	T03ICD_STD	ICD-10 Code and Description	The International Classification of Diseases, Tenth Revision (ICD-10) code and description (e.g., C22.1 - Intrahepatic bile duct carcinoma)
Cancer Medical Treatment History	T03PRIOR	Prior Malignancy	If the participant had a prior malignancy, recorded type(s) of cancer. If the participant has not had a prior malignancy, recorded as 'None'.
Cancer Medical Treatment History	T03SMOKE_STD	Smoking History	The participant's smoking history (e.g., former)
Cancer Medical Treatment History	T03SMOKEDY	Smoking Packs Per Day	If the participant is a former or current smoker, recorded average number of packs per day
Cancer Medical Treatment History	T03SMOKEYR	Smoking Years as Smoker	If the participant is a former or current smoker, recorded average number of years smoked
Cancer Medical Treatment History	T03PRIORLINES	Lines of Prior Therapy	The number of prior lines of therapy for the cancer being treated on TAPUR Study (e.g., 2)
Cancer Medical Treatment History	T03SURQ	Cancer Related Surgeries	Indicates if the participant has had any cancer related surgeries prior to TAPUR Study
Cancer Medical Treatment History	T03RADQ	Cancer Related Radiation Therapies	Indicates if the participant has had any cancer related radiation therapies prior to TAPUR Study
Cancer Medical Treatment History	T03SYSQ	Cancer Related Systemic Therapies	Indicates if the participant has had any cancer related systemic therapies prior to TAPUR Study
Genomic Profiling Test Results	LibraryID	Library Participant ID	Unique identifier for each participant across TAPUR Study data sets in the ASCO data library
Genomic Profiling Test Results	gene_go	Gene/Status Name	The gene or status name (each row represents one gene or status from the genomic profiling test)
Genomic Profiling Test Results	is_panel_negative_go	Panel Negative	A boolean (true/false) value indicating if a gene or biomarker was tested but had no reported alterations
Genomic Profiling Test Results	mutation	Mutation	The normalized mutation name
Genomic Profiling Test Results	mutation_text	Mutation Text	The mutation name as extracted from the report
Genomic Profiling Test Results	mutation_type	Mutation Type	If the gene is a panel negative, records the type of alteration the panel negative gene panel tested (e.g., SNV, CNV, Rearrangement)
Genomic Profiling Test Results	go_variant	Variant	The combination of the gene name and mutation name
Genomic Profiling Test Results	status	Status	The normalized biomarker status
Genomic Profiling Test Results	status_text	Status Text	The biomarker status as extracted from the report
Genomic Profiling Test Results	value	Value	The combination of value and value units as found in the report
Genomic Profiling Test Results	method	Method	The testing method (e.g., DNA-Seq, NGS)
Genomic Profiling Test Results	germline	Germline	The germline status if applicable
Genomic Profiling Test Results	germline_text	Germline Text	The exact test provided in the report pertaining to germline results
Genomic Profiling Test Results	is_vus	VUS	A boolean (true/false) value indicating if a variant is a variant of unknown significance
Genomic Profiling Test Results	reported	Reported	A boolean (true/false) value indicating if a gene or biomarker was reported in the testing panel
Genomic Profiling Test Results	test	Test	Genomic profiling test type (e.g., Foundation, Caris)
Genomic Profiling Test Results	report_date	Report Time Interval	Time interval between genomic profiling test report results and baseline visit in days. Note that all time intervals are calculated from the baseline visit so negative intervals indicate days before the baseline visit.
Genomic Profiling Test Results	specimen_type	Specimen Type	Type of specimen used for genomic profiling test (e.g., tissue, blood)
Genomic Profiling Test Results	collected_date	Collected Time Interval	Time interval between when specimen collection used for genomic profiling test and baseline visit in days. Note that all time intervals are calculated from the baseline visit so negative intervals indicate days before the baseline visit.
Genomic Profiling Test Results	received_date	Received Time Interval	Time interval between when specimen was received by genomic profiling test laboratory and baseline visit in days. Note that all time intervals are calculated from the baseline visit so negative intervals indicate days before the baseline visit.
Physical Exam	LibraryID	Library Participant ID	Unique identifier for each participant across TAPUR Study data sets in the ASCO data library
Physical Exam	FolderName	Visit Type	Indicates study visit when data was collected (i.e., baseline, end of study treatment). Note that a participant may have up to two record rows in this data set and each row represents one physical exam for a given time point.
Physical Exam	BLHT	Height	Participant's height recorded in feet and inches (e.g., 5.4)
Physical Exam	BLWT	Weight	Participant's weight recorded in pounds (lbs)
Physical Exam	BLSBP	Blood pressure systolic	Participant's systolic blood pressure recorded in mm Hg
Physical Exam	BLDBP	Blood pressure diastolic	Participant's diastolic blood pressure recorded in mm Hg
Physical Exam	BLPLS	Pulse rate	Participant's pulse rate recorded in beats per minute (bpm)
Physical Exam	BLTEMP	Temperature	Participant's temperature recorded in degrees Fahrenheit (°F)
Physical Exam	BLECOGDT	Performance Status Time Interval	Time interval between participant's performance status assessment using the Eastern Cooperative Oncology Group (ECOG) grading system and baseline visit in days. Note that all time intervals are calculated from the baseline visit so negative intervals indicate days before the baseline visit.

ASCO® CENTRA

Center for Research & Analytics

Data Table	Field Name	Field Label	Description
Physical Exam	BLECOG	Performance Status	Participant's ECOG performance status
Laboratory Values	LibraryID	Library Participant ID	Unique identifier for each participant across TAPUR Study data sets in the ASCO data library
Laboratory Values	FolderName	Visit Type	Indicates study visit when data was collected (i.e., baseline, end of study treatment). Note that a participant may have up to two record rows in this data set and each row represents one laboratory test for a given time point.
Laboratory Values	BLLABDT	Laboratory Time Interval	Time interval between specimen collection for laboratory testing and baseline visit in days. Note that all time intervals are calculated from the baseline visit so negative intervals indicate days before the baseline visit.
Laboratory Values	BLLABMET	Known Hepatic Metastates	Indicates if the participant has known hepatic metastases
Laboratory Values	BLLAB	Laboratory Name and Units	The laboratory test name and unit of measure (e.g., Albumin (g/dl))
Laboratory Values	BLLAB_STD	Laboratory Name Abbreviation	The laboratory test name abbreviated (e.g., ABL)
Laboratory Values	BLLABVAL	Laboratory Value	The laboratory test result value
Study Drug Administration	LibraryID	Library Participant ID	Unique identifier for each participant across TAPUR Study data sets in the ASCO data library
Study Drug Administration	FolderName	Visit Type	Indicates study visit when data was collected (e.g., baseline, end of study treatment). Note that a participant will have multiple record rows in this data set if they received a combination therapy.
Study Drug Administration	CXDRUG1	Dose Drug Name (Study Drug 1)	The drug name for the therapy the participant received on TAPUR. Note that if they received a combination therapy only one drug name will be recorded in this field and the second drug name will be recorded in the CXDRUG2 field.
Study Drug Administration	CXDOS1	Dose Administered (Study Drug 1)	Participant's dose administered or taken
Study Drug Administration	CXSCHED1	Dose Schedule (Study Drug 1)	Dose schedule or units (e.g., mg/dose)
Study Drug Administration	CXROUTE1	Dose Route (Study Drug 1)	Dose route (e.g., IV)
Study Drug Administration	CXFIRSTCYC1	Dose Time Interval (Study Drug 1)	Time interval between the participant's study drug administration and baseline visit in days
Study Drug Administration	CXDRUG2	Dose Drug Name (Study Drug 2)	The drug name for the therapy the participant received on TAPUR. Note that a participant will only have data in the 'Study Drug 2' columns if they received a combination therapy.
Study Drug Administration	CXDOS2	Dose Administered (Study Drug 2)	Participant's dose administered or taken
Study Drug Administration	CXSCHED2	Dose Schedule (Study Drug 2)	Dose schedule or units (e.g., mg/dose)
Study Drug Administration	CXROUTE2	Dose Route (Study Drug 2)	Dose route (e.g., IV)
Study Drug Administration	CXFIRSTCYC2	Dose Time Interval (Study Drug 2)	Time interval between the participant's study drug administration and baseline visit in days
Tumor Measurements and Evaluation	LibraryID	Library Participant ID	Unique identifier for each participant across TAPUR Study data sets in the ASCO data library
Tumor Measurements and Evaluation	ASDT	Assessment Time Interval	Time interval between tumor assessment and evaluation and baseline visit in days
Tumor Measurements and Evaluation	TUMWEEK	Tumor Assessment Timepoint	Tumor assessment and evaluation timepoint in weeks post-baseline (e.g., 8). Per the TAPUR Study protocol, tumor assessments taken at baseline will be repeated every 8 weeks for the first 16 weeks then every 12 weeks thereafter. Note that the baseline visit is recorded as '0' weeks.
Tumor Measurements and Evaluation	RESP	Physician Response Assessment	Treating physician's response assessment for evaluation timepoint per RECIST v1.1 criteria (e.g., PR)
Tumor Measurements and Evaluation	STEVRESPRECIST	Response Assessment Aligns RECIST	Indicates if the treating physician's response aligns with RECIST v1.1 criteria
Tumor Measurements and Evaluation	STEVRESPRECISTSP	Response Assessment Rationale	If the treating physician's response does not align with RECIST v1.1, recorded rationale for treating physician's response assessment (e.g., pseduo-progression)
Tumor Measurements and Evaluation	EVAL_B_Q	New Lesion(s)	Indicates if a new lesion was detected on scan at this evaluation timepoint
Tumor Measurements and Evaluation	STEVLSUM	Target Lesion Sum	The sum of the participant's target lesion measurements recorded in milimeters (e.g., 30) at this evaluation timepoint
Tumor Measurements and Evaluation	LES_NTAR_Q	Non-Target Lesion(s)	Indicates if the participant has non-target lesion(s) assessed at this evaluation timepoint
Tumor Measurements and Evaluation	STEVNT	Non-Target Lesion(s) Present	Indicates if at least one non-target lesion is present at this evaluation timepoint
Tumor Measurements and Evaluation	STEVNTPROGRESS	Unequivocal Progression Non-Target Lesion(s)	Indicates if there has been unequivocal progression of non-target lesion(s) at this evaluation timepoint
Adverse Events	LibraryID	Library Participant ID	Unique identifier for each participant across TAPUR Study data sets in the ASCO data library
Adverse Events	AETERM_STD	Event Term	Adverse event term based on Common Terminology Criteria for Adverse Events (CTCAE v4.0)
Adverse Events	AETERMNUM	MedDRA Code	The Medical Dictionary for Regulatory Activities (MedDRA) v12.0 code that corresponds with the event term
Adverse Events	ONSETDT	Onset Time Interval	Time interval between adverse event onset and baseline visit in days
Adverse Events	AEGRADE	Severity Grade	The severity grade per CTCAE v4.0. Note that if the participant has a grade 5 severe adverse event recorded, the death time interval is recorded in the vital status data set.
Adverse Events	SAE	SAE or AESI	Indicates if event is a serious adverse event (SAE) or event of special interest (AESI)
Adverse Events	SAETYPE	SAE Type	If serious, recorded type of serious event (e.g., hospitalization)
Adverse Events	AERELATE	Relation to Study Drug	Clinical site's most recent assessment of adverse event being related to study drug treatment (e.g., probably)
Adverse Events	AEDISPROG	Relation to Disease Progression	Clinical site's most recent assessment of adverse event being related to disease progression
Adverse Events	AESTATUS	Status	The most recent status (e.g., recovered) recorded
Adverse Events	AERESDT	Resolution Time Interval	Time interval between adverse event resolution and baseline visit in days
Adverse Events	SAEDEATH	Primary Cause of Death	The primary cause of the participant's death
End of Study Treatment	LibraryID	Library Participant ID	Unique identifier for each participant across TAPUR Study data sets in the ASCO data library
End of Study Treatment	ENDDRUG1	Final Dose Drug Name (Study Drug 1)	The drug name for the therapy the participant received on TAPUR. Note that if they received a combination therapy only one drug name will be recorded in this field and the second drug name will be recorded in the ENDDRUG2 field.
End of Study Treatment	ENDDOS1	Final Dose Administered (Study Drug 1)	Participant's final dose administered or taken
End of Study Treatment	ENDSCHEDULE1	Final Dose Schedule (Study Drug 1)	Final dose schedule or units (e.g., mg/dose)
End of Study Treatment	ENDROUTE1	Final Dose Route (Study Drug 1)	Final dose route (e.g., IV)
End of Study Treatment	ENDDOSDT1	Treatment Discontinuation Time Interval (Study Drug 1)	Time interval between the participant's final dose and baseline visit in days
End of Study Treatment	ENDDRUG2	Final Dose Drug Name (Study Drug 2)	The drug name for the therapy the participant received on TAPUR. Note that a participant only have data in the 'Study Drug 2' columns if they received a combination therapy.

ASCO® CENTRA

Center for Research & Analytics

Data Table	Field Name	Field Label	Description
End of Study Treatment	ENDDOS2	Final Dose Administered (Study Drug 2)	Participant's final dose administered or taken
End of Study Treatment	ENDSCHEDULE2	Final Dose Schedule (Study Drug 2)	Final dose schedule or units (e.g., mg/dose)
End of Study Treatment	ENDROUTE2	Final Dose Route (Study Drug 2)	Final dose route (e.g., IV)
End of Study Treatment	ENDDOSDT2	Treatment Discontinuation Time Interval (Study Drug 2)	Time interval between the participant's final dose and baseline visit in days
End of Study Treatment	ENDVISITDT	End of Study Report Time Interval	Time interval between the participant's end of study visit report and baseline visit in days
End of Study Treatment	ENDVIS	End of Study Treatment Visit Performed	Indicates if an end of study treatment visit was performed
End of Study Treatment	ENDVISDT	End of Study Visit Time Interval	Time interval between the participant's end of study visit and baseline visit in days
End of Study Treatment	ENDVISREAV2_STD	Missed End of Study Visit Reason	If an end of study treatment visit was not performed, recorded primary reason for missed visit
End of Study Treatment	ENDDISC	Study Drug Discontinuation Decision	The individual(s) who made the decision to discontinue study drug administration (e.g., treating physician). Note that this field is recorded as a checkbox and may have multiple responses.
End of Study Treatment	ENDWHYDISC	Study Drug Discontinuation Reason	The primary reason study drug administration was permanently discontinued (e.g., tumor progression)
End of Study Treatment	ENDTUMOREVAL	Post-Baseline Tumor Evaluation Performed	Indicates if at least one tumor assessment and evaluation was performed after the participant's baseline visit
End of Study Treatment	ENDTUMORPROGRESS	Post-Baseline Tumor Evaluation Progression	If the participant had at least one post-baseline tumor evaluation performed, indicates if the most recent evaluation demonstrated tumor progression
End of Study Treatment	ENDTUMOREXPER	Post-Baseline Progression Related Event	If the participant did not have at least one post-baseline tumor evaluation performed or the most recent evaluation did not demonstrate tumor progression, recorded related participant experience leading to end of study treatment (e.g., Reportable AE or SAE due to disease or tumor progression). Note that if the participant did not experience any events related to clinical or disease progression, this will be recorded as 'None of the above'.
Vital Status	LibraryID	Library Participant ID	Unique identifier for each participant across TAPUR Study data sets in the ASCO data library
Vital Status	STVITAL_STD	Vital Status	Participant's most recent vital status. Note that if the participant expired within 30 days of last dose death is also recorded in the adverse event data set.
Vital Status	STDEATHDCAUSE_STD	Cause of Death	If the participant is deceased, recorded primary cause of death
Vital Status	STICD10_STD	Death ICD-10 Code	If the participant is deceased and death is due to tumor or disease progression, recorded ICD-10 diagnosis code and description
Vital Status	death_dt	Death Time Interval	If the participant is deceased, time interval between death and baseline visit in days
Vital Status	recent_followup	Most Recent Contact Time Interval	Time interval between most recent contact with the participant and baseline visit in days